Real World Data Survival Outcomes of First Line Immunotherapy with Pembrolizumab in High Expressers with stage IV Non-Small Cell Lung Cancer. Radiol Oncol [Internet]. 2026 Sep. 2 [cited 2026 Sep. 22];60(3):450-8. Available from: https://www.radioloncol.com/index.php/ro/article/view/4876